Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Quetiapine 200 mg vs SEROQUEL 200 mg in Thai Healthy Volunteers (Fasting, Crossover)
TCTR20260618001Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of quetiapine (2 arms), sponsored by Bio-innova. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
quetiapine
Beyond the preview
Go deeper on TCTR20260618001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260618001.